Cargando…

Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues

Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully a...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Ruizhi, Knoll, Jasmin, Harland, Niklas, Amend, Bastian, Enderle, Markus D., Linzenbold, Walter, Abruzzese, Tanja, Kalbe, Claudia, Kemter, Elisabeth, Wolf, Eckhard, Schenk, Martin, Stenzl, Arnulf, Aicher, Wilhelm K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036380/
https://www.ncbi.nlm.nih.gov/pubmed/35466714
http://dx.doi.org/10.1177/09636897221080943
_version_ 1784693511855013888
author Geng, Ruizhi
Knoll, Jasmin
Harland, Niklas
Amend, Bastian
Enderle, Markus D.
Linzenbold, Walter
Abruzzese, Tanja
Kalbe, Claudia
Kemter, Elisabeth
Wolf, Eckhard
Schenk, Martin
Stenzl, Arnulf
Aicher, Wilhelm K.
author_facet Geng, Ruizhi
Knoll, Jasmin
Harland, Niklas
Amend, Bastian
Enderle, Markus D.
Linzenbold, Walter
Abruzzese, Tanja
Kalbe, Claudia
Kemter, Elisabeth
Wolf, Eckhard
Schenk, Martin
Stenzl, Arnulf
Aicher, Wilhelm K.
author_sort Geng, Ruizhi
collection PubMed
description Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully and raised high hopes for better outcome. However, other studies were rather disappointing. We therefore developed a novel cell injection technology to deliver viable cells in the urethral sphincter complex by waterjet instead of using injection needles. We hypothesized that the risk of tissue injury and loss of cells could be reduced by a needle-free injection technology. Muscle-derived cells were obtained from young male piglets and characterized. Upon expansion and fluorescent labeling, cells were injected into cadaveric tissue samples by either waterjet or injection needle. In other experiments, labeled cells were injected by waterjet in the urethra of living pigs and incubated for up to 7 days of follow-up. The analyses documented that the cells injected by waterjet in vitro were viable and proliferated well. Upon injection in live animals, cells appeared undamaged, showed defined cellular somata with distinct nuclei, and contained intact chromosomal DNA. Most importantly, by in vivo waterjet injections, a significantly wider cell distribution was observed when compared with needle injections (P < .05, n ≥ 12 samples). The success rates of waterjet cell application in living animals were significantly higher (≥95%, n = 24) when compared with needle injections, and the injection depth of cells in the urethra could be adapted to the need by adjusting waterjet pressures. We conclude that the novel waterjet technology injects viable muscle cells in tissues at distinct and predetermined depth depending on the injection pressure employed. After waterjet injection, loss of cells by full penetration or injury of the tissue targeted was reduced significantly in comparison with our previous studies employing needle injections.
format Online
Article
Text
id pubmed-9036380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90363802022-04-26 Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues Geng, Ruizhi Knoll, Jasmin Harland, Niklas Amend, Bastian Enderle, Markus D. Linzenbold, Walter Abruzzese, Tanja Kalbe, Claudia Kemter, Elisabeth Wolf, Eckhard Schenk, Martin Stenzl, Arnulf Aicher, Wilhelm K. Cell Transplant Original Article Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully and raised high hopes for better outcome. However, other studies were rather disappointing. We therefore developed a novel cell injection technology to deliver viable cells in the urethral sphincter complex by waterjet instead of using injection needles. We hypothesized that the risk of tissue injury and loss of cells could be reduced by a needle-free injection technology. Muscle-derived cells were obtained from young male piglets and characterized. Upon expansion and fluorescent labeling, cells were injected into cadaveric tissue samples by either waterjet or injection needle. In other experiments, labeled cells were injected by waterjet in the urethra of living pigs and incubated for up to 7 days of follow-up. The analyses documented that the cells injected by waterjet in vitro were viable and proliferated well. Upon injection in live animals, cells appeared undamaged, showed defined cellular somata with distinct nuclei, and contained intact chromosomal DNA. Most importantly, by in vivo waterjet injections, a significantly wider cell distribution was observed when compared with needle injections (P < .05, n ≥ 12 samples). The success rates of waterjet cell application in living animals were significantly higher (≥95%, n = 24) when compared with needle injections, and the injection depth of cells in the urethra could be adapted to the need by adjusting waterjet pressures. We conclude that the novel waterjet technology injects viable muscle cells in tissues at distinct and predetermined depth depending on the injection pressure employed. After waterjet injection, loss of cells by full penetration or injury of the tissue targeted was reduced significantly in comparison with our previous studies employing needle injections. SAGE Publications 2022-04-23 /pmc/articles/PMC9036380/ /pubmed/35466714 http://dx.doi.org/10.1177/09636897221080943 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Geng, Ruizhi
Knoll, Jasmin
Harland, Niklas
Amend, Bastian
Enderle, Markus D.
Linzenbold, Walter
Abruzzese, Tanja
Kalbe, Claudia
Kemter, Elisabeth
Wolf, Eckhard
Schenk, Martin
Stenzl, Arnulf
Aicher, Wilhelm K.
Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title_full Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title_fullStr Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title_full_unstemmed Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title_short Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
title_sort replacing needle injection by a novel waterjet technology grants improved muscle cell delivery in target tissues
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036380/
https://www.ncbi.nlm.nih.gov/pubmed/35466714
http://dx.doi.org/10.1177/09636897221080943
work_keys_str_mv AT gengruizhi replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT knolljasmin replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT harlandniklas replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT amendbastian replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT enderlemarkusd replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT linzenboldwalter replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT abruzzesetanja replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT kalbeclaudia replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT kemterelisabeth replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT wolfeckhard replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT schenkmartin replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT stenzlarnulf replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues
AT aicherwilhelmk replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues